Treatment of Progressive Supranuclear Palsy
There is no cure or disease-modifying therapy for progressive supranuclear palsy; treatment is entirely symptomatic and supportive, centered on multidisciplinary rehabilitation with physical therapy, speech therapy, and occupational therapy, while levodopa can be trialed but rarely provides meaningful benefit 1, 2, 3.
Current Treatment Reality
PSP remains a devastating diagnosis with no pharmacologic interventions that alter disease progression. All completed clinical trials of disease-modifying agents have failed 1, 4. The evidence provided about DBS and invasive therapies 5 pertains exclusively to Parkinson's disease and is not applicable to PSP—in fact, recent evidence confirms DBS in PSP is largely ineffective, with only modest and inconsistent benefits in highly selected parkinsonism-predominant phenotypes 6.
Symptomatic Pharmacotherapy
Levodopa: Most commonly prescribed medication (used in 87% of patients), but provides meaningful benefit in only a minority 2
- Trial doses up to 1000-1500 mg/day before declaring treatment failure
- PSP-parkinsonism phenotype most likely to respond, though still limited
- Discontinue if no benefit after 3 months
Antidepressants: Second most common prescription for mood symptoms 2
Other medications: Amantadine, anticholinergics, and dopamine agonists have been tried but lack evidence and are generally ineffective 3
Rehabilitation: The Core Intervention
Intensive, multidisciplinary rehabilitation is the only intervention with demonstrated benefit 7, 8:
Physical Therapy Components
- Aerobic training: Treadmill-based gait training with visual cues and auditory feedback
- Balance training: Reduces fall frequency (documented improvement in Berg Balance Scale scores) 7
- Transfer training: Critical for maintaining independence 8
- Goal-based motor-cognitive exercises: Combined approach superior to single-modality therapy 7
A 4-week intensive rehabilitation program showed significant improvements in:
- Total PSP Rating Scale scores
- Gait subscores
- Balance (Berg Balance Scale)
- Six-minute walking distance
- Reduction in fall frequency 7
Important caveat: Robotic-assisted gait training (Lokomat) provides no additional benefit over standard treadmill training with cues, so simpler approaches are equally effective 7.
Speech and Swallowing Therapy
- Dysphagia is nearly universal and life-threatening
- Early speech-language pathology involvement essential
- Swallowing evaluation and strategies to prevent aspiration 3
Occupational Therapy
- Adaptive equipment for activities of daily living
- Home safety modifications to prevent falls
- Assistive devices: Walking aids needed at mean 21 months from symptom onset; wheelchairs at 40 months 2
Diagnostic Considerations Affecting Treatment
Mean time from symptom onset to diagnosis is 15 months, with 41% of patients initially misdiagnosed (most commonly as Parkinson's disease) 2. This delay matters because:
- Earlier multidisciplinary intervention may slow functional decline
- Inappropriate dopaminergic escalation in misdiagnosed patients causes side effects without benefit
- Consulting a movement disorder specialist expedites accurate diagnosis 2
Clinical Pitfalls to Avoid
- Prolonged levodopa trials: Don't continue ineffective dopaminergic therapy indefinitely—3 months is sufficient
- Expecting DBS benefit: Unlike Parkinson's disease, DBS is not an established treatment for PSP 6
- Delaying rehabilitation: Physical therapy should begin at diagnosis, not after significant functional decline
- Ignoring dysphagia: Aspiration pneumonia is a leading cause of death; proactive swallowing assessment is mandatory 3
- Single-discipline approach: PSP requires coordinated neurology, physical therapy, speech therapy, occupational therapy, and palliative care 3, 9
Prognosis and Realistic Expectations
- PSP-Richardson syndrome: 5-7 years survival with rapid progression 10
- PSP-parkinsonism: 8-12 years with slower decline 10
- No treatment alters these trajectories; focus is on quality of life and symptom management
Future Directions
Tau-targeted immunotherapy and gene therapy trials are ongoing 1, but currently offer no clinical benefit outside research protocols. Enrollment in clinical trials should be discussed with appropriate patients, but without expectation of therapeutic benefit.